Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients

Completed

• Conditions: Covid19

• Registration Number: NCT04982263
• Lead Sponsor: Sohag University

Brief Summary

The role of the coagulation parameters in predicting the severity of COVID-19 disease will be assessed

Detailed Description

In COVID-19 patients the coagulation parameters Prothrombin concentration (PC), Activated Partial Thromboplastin Time (aPTT), D Dimer, Antithrombin III (ATIII) and Fibrinogen are measured and correlation with disease severity is to be investigated

Study Timeline

• Study Start: 2021-02-01
• Primary Completion: 2021-05-31
• Study Completion: 2021-05-31
• Status Verified: 2021-07
• Study First Submitted: 2021-07-26
• Study First Submitted QC: 2021-07-27
• Last Update Submitted: 2021-07-27
• Study First Posted: 2021-07-29
• Last Update Posted: 2021-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 125

Inclusion Criteria

● Confirmed cases with COVID 19

Exclusion Criteria

● Known history of blood coagulopathy disorder

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
correlation of disease severity with results of laboratory test	Baseline results of coagulation profile and baseline disease severity assessment	The results of blood coagulation profile will be correlated with degree of severity of illness

Secondary Outcome Measures

Name	Time	Method
Agreement of abnormalities in coagulation profile with measured inflammatory markers	baseline measurement of inflammatory markers	The inflammatory markers will be measured and correlation with abnormalities in coagulation profile will be assessed

Trial Locations

Locations (1)

Sohag University; 🇪🇬 Sohag, Egypt